Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous IL-2 in HIV
NCT00001357Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 1993
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Maximum Tolerated Dose. Started Aug 1993; status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001357.